Role of Uralyt-U in Patients With Hyperuricemia

NAUnknownINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

September 30, 2020

Study Completion Date

October 31, 2020

Conditions
Uric Acid StonesHyperuricemia
Interventions
DRUG

Febuxostat

Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.

DRUG

Uralyt-U

Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.

Trial Locations (1)

200072

RECRUITING

Department of Nephrolgoy, Shanghai 10th People's Hospital, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ai Peng

OTHER

NCT04352153 - Role of Uralyt-U in Patients With Hyperuricemia | Biotech Hunter | Biotech Hunter